

AD-A234 622

CONTRACT NO.: DAMD17-87-C-7173

TITLE: BIOLOGICAL SIGNIFICANCE OF THE IMMUNE RESPONSE TO  
HTLV-III/HAV

PRINCIPAL INVESTIGATOR: DANI P. BOLOGNESI

PI ADDRESS: Duke University Medical Center  
P.O. Box 2926  
Durham, North Carolina 27710

REPORT DATE: DECEMBER 14, 1990

TYPE OF REPORT: FINAL

PREPARED FOR: U.S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND  
FORT DETRICK  
FREDERICK, MARYLAND 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;  
distribution unlimited

The findings in this report are not to be construed as an  
official Department of the Army position unless so designated by  
other authorized documents.

DTIC  
ELECTE  
APR 10 1991  
S B D

1990 FILE COPY

91 4 09 108

## REPORT DOCUMENTATION PAGE

Form Approved  
OMB No. 0704-0188

1a. REPORT SECURITY CLASSIFICATION			1b. RESTRICTIVE MARKINGS			
2a. SECURITY CLASSIFICATION AUTHORITY Unclassified			3. DISTRIBUTION AVAILABILITY OF REPORT Approved for public release; distribution unlimited			
2b. DECLASSIFICATION/DOWNGRADING SCHEDULE						
4. PERFORMING ORGANIZATION REPORT NUMBER(S)			5. MONITORING ORGANIZATION REPORT NUMBER(S)			
6a. NAME OF PERFORMING ORGANIZATION Duke University Medical Center		6b. OFFICE SYMBOL (If applicable)		7a. NAME OF MONITORING ORGANIZATION		
6c. ADDRESS (City, State, and ZIP Code) P.O. Box 2926 Durham, NC 27710			7b. ADDRESS (City, State, and ZIP Code)			
8a. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical Research & Development Command		8b. OFFICE SYMBOL (If applicable)		9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER DAMD17-87-C-7173		
8c. ADDRESS (City, State, and ZIP Code) Fort Detrick Frederick, Maryland 21702-5012			10. SOURCE OF FUNDING NUMBERS			
			PROGRAM ELEMENT NO 63105A	PROJECT NO. 3M2- 63105DH29	TASK NO. AD	WORK UNIT ACCESSION NO. WUDA313254
11. TITLE (Include Security Classification) (U) Biological Significance of the Immune Response to HTLV-III/LAV						
12. PERSONAL AUTHOR(S) Dani P. Bolognesi						
13a. TYPE OF REPORT Final		13b. TIME COVERED FROM 8/15/87 TO 8/15/90		14. DATE OF REPORT (Year, Month, Day) 1990 December 14		15. PAGE COUNT
16. SUPPLEMENTARY NOTATION						
17. COSATI CODES			18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)			
FIELD	GROUP	SUB-GROUP	RA 1; Aids; HIV; Vaccine Development;			
06	03		Virology; Immunology			
06	13					
19. ABSTRACT (Continue on reverse if necessary and identify by block number)						
Comprehensive studies have been conducted to determine seroreactivity of HIV infected individuals to well defined epitopes on the virus envelope. These have included regions which serve as targets for neutralizations and ADCC mediating antibodies. The principal neutralizing domain (PND) of HIV lies within the third hypervariable domain and is represented by a disulfide linked loop (residues 303-337). This region contains both variable and conserved epitopes. The ADCC targets are present in both gp120 and gp41 and are represented by conserved domains.						
20. DISTRIBUTION/AVAILABILITY OF ABSTRACT <input type="checkbox"/> UNCLASSIFIED/UNLIMITED <input checked="" type="checkbox"/> SAME AS RPT <input type="checkbox"/> DTIC USERS			21. ABSTRACT SECURITY CLASSIFICATION Unclassified			
22a. NAME OF RESPONSIBLE INDIVIDUAL Mary Frances Bostian			22b. TELEPHONE (Include Area Code) 301-663-7325		22c. OFFICE SYMBOL SGRD-RMI-S	

## FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

N/A Where copyrighted material is quoted, permission has been obtained to use such material.

DB Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

DB Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.

DB In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Animal Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

DB For the protection of human subjects, the investigator(s) have adhered to policies of applicable Federal Law 45CFR46.

Fai Bologni  
PI Signature

1/21/91  
Date

## Army Terminal Report

The goals of the contract were to identify, map and characterize important target epitopes on the envelope of HIV. We have been successful in identifying four of these although a number of others have been studied. Reference is made to Figure 1 which is a reasonably up-to-date road map of the HIV envelope drawn from the work of many laboratories.

Our specific contributions to this were:

- 1) Identification of the dominant neutralizing epitope of HIV gp120 (AA 303-337).
- 2) Identification of two ADCC sites in gp120 (AA 315-329 and 474-518).
- 3) Identification of a dominant ADCC site in gp41 (AA 644-663).

In brief, the dominant neutralizing epitope, often referred to as V3 and more recently as the principle neutralizing determinant (PND), has been characterized extensively by us and a host of other laboratories. This site is now considered to represent region of the virus which is essential for infectivity and operates at a step post-binding of the exterior glycoprotein to CD4. It is believed to be intimately involved in virus penetration in relation to the fusion process. Our specific contributions to this process are as follows:

- 1) Immunodominant epitopes in the HIV outer envelope were identified (7) as well as the notion that HIV contained a dominant neutralization site (8). Using three independent approaches, the epitope responsible was finely mapped to the V3 loop (9,10,11).
- 2) Subsequently, a number of studies were conducted to maximize the immunogenicity of this region including its linkage to a T-cell epitope of gp120 (12). This construct forms the basis of a vaccine candidate described in this application.
- 3) The mechanism of virus neutralization via this epitope was demonstrated to occur at a step post binding of the virus to the CD4 receptor and closely linked to the fusion process (13).
- 4) The variability of this region among natural HIV isolates has been extensively studied (14). From this and other work, the notion of the prevalence of viruses resembling the MN isolate was established.

These findings raise the possibility that natural HIV isolates can be grouped into neutralization families, whereby a cocktail of representative V3 domains could be used to induce broadly cross neutralizing antibodies.

- 5) More in depth analysis of sub-regions of the V3 loop has identified conserved domains which when separated from the variable regions can themselves induce antibodies which neutralize divergent isolates (15). Such more universal epitopes will make the cocktail approach likelier to achieve.
- 6) Studies have been performed to better define the role of the V3 loop in the process of virus infection and target cell specificity. Using site directed mutagenesis of infectious HIV clones, the critical role of certain amino acid residues in the conserved loop crown has been established (16).

The biological role of this domain continues to grow in importance as antibodies to have recently been implicated as the best correlate for vaccine protection of chimps against HIV infection and as possible deterrents against mother/infant transmission of the virus in humans.

We have also contributed extensively to the understanding of the phenomenon of ADCC as it relates to HIV:


- 1) The phenomenon of ADCC as it applies to the HIV envelope was originally described (1). Subsequently, the correlates of this defense mechanism with disease progression were defined (2). More recently, the intimate details of the components of this unique phenomenon have been identified (3,4) as well as the fine specificity of ADCC epitopes on HIV envelope (5). This work, in aggregate, has spawned a clinical trial which is in progress (6).

Throughout the course of these studies, a number of important biological systems were also developed and paired with sensitive and specific assays designed to study various properties of HIV and the immune responses to it (7,8,9,10,15,17).

Accession For	
NTIS GRA&I	<input checked="" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By	
Distribution/	
Availability Codes	
Dist	Avail And/or Special
A-1	

**FIGURE 1**

# Selected Functional and Immunogenic Sites of the HIV-1 Envelope



1. Lierly, H.K., Matthews, T.J., Langlois, A.J., Bolognesi, D.P., and Weinhold, K.J. Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack. *PNAS* 84:4601-4605, 1987.
2. Weinhold, K.J., Lierly, H.K., Matthews, T.J., Tyler, D.S., Ahearne, P.M., Stine, K.C., Langlois, A.J., Durack, D.T., and Bolognesi, D.P. Cellular anti-gp120 cytolytic reactivities in HIV-1 seropositive individuals. *Lancet* (April 23), 902-904, 1988.
3. Tyler, D.S., Stanley, S.D., Nastala, C.L., Lierly, H.K., Matthews, T.J., Bolognesi, D.P., and Weinhold, K.J. Antibody-directed anti-HIV-1 cellular cytotoxicity: Role of NK/K cells armed with gp120-specific antibodies in therapeutic and vaccine strategies. In: *Vaccines 89*, (R.A. Lerner, H. Ginsberg, R.M. Chanock, and F. Brown, Eds.), Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp.155-158, 1989.
4. Tyler, D.S., Stanley, S.D., Nastala, C.A., Austin, A.A., Bartlett, J.A., Stine, K.C., Lierly, H.K., Bolognesi, D.P., and Weinhold, K.J. Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. *J. of Immunol.* 144:3375-3384, 1990.
5. Tyler, D.S., Stanley, S.D., Zolla-Pazner, S., Gorny, M.K., Shadduck, P.P., Langlois, A.J., Matthews, T.J., Bolognesi, D.P., Palker, T.J. and Weinhold, K.J. Identification of sites within gp41 which serve as targets for antibody-dependent cellular cytotoxicity using human monoclonal antibodies. *J. of Immunol.*, 1990, in press.
6. Interleukin-2 augmentation of specific anti-HIV immune responses: Phase I trial of the combination of 3'-Azido-3'-Deoxythymidine (Zidovudine) and recombinant interleukin-2 in patients with asymptomatic HIV infection associated with lymphadenopathy (Walter Reed Stage II)
7. Palker, T.J., Matthews, T.J., Clark, M.E., Cianciolo, G.J., Randall, R.R., Langlois, A.J., White, G.C., Safai, B., Snyderman, R., Bolognesi, D.P., and Haynes, B.F. A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitope. *PNAS* 84:2479-2483, 1987.
8. Putney, S.D., Matthews, T.J., Robey, W.G., Lynn, D.L., Robert-Guroff, M., Mueller, W.T., Langlois, A.J., Ghrayeb, J., Petteway, Jr., S.T., Weinhold, K.J., Fischinger, P.J., Wong-Staal, F., Gallo, R.C., and Bolognesi, D.P. HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. *Science* 234:1392-1395, 1986.

9. Palker, T.J., Clark, M.E., Langlois, A.J., Matthews, T.J., Weinhold, K.J., Randall, R.R., Bolognesi, D.P., and Haynes, B.F., Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. PNAS 85, 1988.
10. Rusche, J.R., Javaherian, K., McDanal, C., Petro, J., Lynn, D.L., Grimailla, R., Langlois, A., Gallo, R.C., Arthur, L.O., Fischinger, P.J., Bolognesi, D.P., Putney, S.D., and Matthews, T.J. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. PNAS 85:3198-3202, 1988.
11. Kenealy, W.R., Matthews, T.J., Ganfield, M., Langlois, A.J., Waselefsky, D.M., and Petteway, Jr., S.R., Antibodies from human immunodeficiency virus-infected individuals bind to a short amino acid sequence that elicits neutralizing antibodies in animals. AIDS Res and Human Retrovir 5,2:173-182, 1989.
12. Palker, T.J., Matthews, T.J., Langlois, A.J., Tanner, M.E., Martin, M.E., Searce, R.M., Kim, J.E., Berzofsky, J.A., Bolognesi, D.P., and Haynes, B.F. Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes. J of Immunol. 142:3612-3619, 1989.
13. Skinner, M.A., Langlois, A.J., McDanal, C.B., McDougal, J.S., Bolognesi, D.P., and Matthews, T.J. Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. J. Virol. 62:4195-4200, 1988.
14. LaRosa, G.J., Davide, J.P., Weinhold, K.J., Waterbury, J.A., Profy, A.T., Lewis, J.A., Langlois, A.J., Dreesman, G.R., Boswell, R.N., Shadduck, P., Holley, L.H., Karplus, M., Bolognesi, D.P., Matthews, T.J., Emini, E.A., and Putney, S.D. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 249:932-935, 1990.
15. Javaherian, K., Langlois, A.J., LaRosa, G.J., Profy, A.T., Bolognesi, D.P., Herlihy, W.C., Putney, S.D., and Matthews, T.J. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science, 1990, in press.
16. Ivanoff, L., Looney, D., McDanal, C., Morris, J., Wong-Staal, F., Petteway, Jr., S., and Matthews, T.J. Alterations of HIV-1 infectivity and neutralization by a single amino acid replacement in the V3 loop domain. J. Virol., 1990, Submitted.
17. Langlois, A.J., Matthews, T.J., Weinhold, K.J., Chaffee, S., Hershfield, M., and Bolognesi, D.P. Detection of HIV-1 neutralizing antibodies by a simple, rapid, colorimetric assay. AIDS Res and Human Retrovir 4,1:63-69, 1988.